Stocks Comparison
Curaleaf vs Usana Health Sciences: revenue, profit, margins and growth compared
Curaleaf brought in $1.3B of revenue in fiscal 2025, Usana Health Sciences $925.3M in fiscal 2025. Revenue changed by -5.0% at Curaleaf and +8.3% at Usana Health Sciences on the year before, so Usana Health Sciences grew faster. Curaleaf kept -18.2% of its revenue as net profit, Usana Health Sciences 1.2%. Free cash flow was $74.3M at Curaleaf and $8.5M at Usana Health Sciences.
Side by side, latest fiscal year
| CURLF | USNA | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2025 (January 3, 2026) |
| Revenue | $1.3B | $925.3M |
| Revenue growth | -5.0% | +8.3% |
| Net income | -$231.1M | $10.8M |
| Net margin | -18.2% | 1.2% |
| Free cash flow | $74.3M | $8.5M |
| Free cash flow margin | 5.9% | 0.9% |
| Earnings per share (diluted) | -$0.35 | $0.58 |
| Cash | $89.2M | $158.4M |
| Debt | $548.7M | n/a |
| Price to earnings | n/a | 25.6 |
| Market value | n/a | $273.8M |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #141 of 742 · Health care | #158 of 742 · Health care |
Over the years
Questions about Curaleaf and Usana Health Sciences
Which is bigger by revenue, Curaleaf or Usana Health Sciences?
Curaleaf is bigger by revenue: $1.3B in fiscal 2025, against $925.3M for Usana Health Sciences in fiscal 2025.
Which keeps more of its revenue as profit, Curaleaf or Usana Health Sciences?
Curaleaf had a net margin of -18.2% in fiscal 2025; Usana Health Sciences had 1.2% in fiscal 2025.
Which grew revenue faster, Curaleaf or Usana Health Sciences?
In their latest fiscal years revenue changed by -5.0% at Curaleaf and +8.3% at Usana Health Sciences.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.